MELANOMA RESEARCH

$16,806P30FY2014CANIH

New York University School Of Medicine, New York NY

Investigators

Linked publications & trials

Paper 39713327 Paper 39713021 Paper 39687626 Paper 39638898 Paper 39613875 Paper 39585979 Paper 39565353 Paper 39541553 Paper 39511422 Paper 39416756 Paper 39386620 Paper 39386533 Paper 39382030 Paper 39379700 Paper 39345451 Paper 39289405 Paper 39240229 Paper 39222027 Paper 39214097 Paper 39208796 Paper 39198446 Paper 39190500 Paper 39185202 Paper 39181563 Paper 39173638 Paper 39167639 Paper 39164233 Paper 39149392 Paper 39121154 Paper 39094749 Paper 39091750 Paper 39091724 Paper 39085604 Paper 39079958 Paper 39072634 Paper 39071292 Paper 39070643 Paper 39070636 Paper 39070624 Paper 39025865 Paper 39002743 Paper 38936360 Paper 38895309 Paper 38871359 Paper 38867045 Paper 38862651 Paper 38862472 Paper 38853977 Paper 38822923 Paper 38802368 Paper 38781214 Paper 38777335 Paper 38773978 Paper 38766195 Paper 38758649 Paper 38738602 Paper 38728430 Paper 38687677 Paper 38659744 Paper 38656316 Paper 38652812 Paper 38640347 Paper 38630987 Paper 38622760 Paper 38608038 Paper 38556137 Paper 38536921 Paper 38530242 Paper 38496571 Paper 38483996 Paper 38474178 Paper 38467678 Paper 38459027 Paper 38453762 Paper 38418917 Paper 38381133 Paper 38352515 Paper 38339062 Paper 38328255 Paper 38328196 Paper 38283617 Paper 38279029 Paper 38272461 Paper 38215744 Paper 38213787 Paper 38206008 Paper 38194610 Paper 38194271 Paper 38187763 Paper 38180236 Paper 38168253 Paper 38165806 Paper 38149950 Paper 38110299 Paper 38106171 Paper 38096821 Paper 38059352 Paper 38048045 Paper 38037605 Paper 38014211

Abstract

The Melanoma Research Program is composed of 24 investigators (17 Full and 7 Associate members) from 10 Departments. The Program has 3 major scientific objectives: 1) Develop new prognostic models for patients with primary melanoma that integrate molecular biomarkers with clinical variables; 2) Discover the biologic heterogeneity of melanoma with emphasis on molecular alterations that are associated with disease progression and drug resistance; and 3) Develop and integrate emerging novel immunotherapeutic approaches with chemotherapeutic and biological therapies in the treatment of melanoma. Drs. Nina Bhardwaj and Iman Osman are the Co-Leaders for this Program. Total funding increased from $2,739,004 to $4,841,572 since the last competitive application. Membership has increased from 19 to 24 members. Publications for the period total 156, of which 23.7% are intra-programmatic, 20.5% are inter-programmatic, and 12.2% are both intra- and inter-programmatic collaborations.

View original record on NIH RePORTER →